Royalty Minority Interest vs Cost Of Revenue Analysis

RPRX Stock

USD 31.03 0.08 0.26%

Royalty Pharma financial indicator trend analysis is much more than just breaking down Royalty Pharma Plc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Royalty Pharma Plc is a good investment. Please check the relationship between Royalty Pharma Minority Interest and its Cost Of Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty Pharma Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Minority Interest vs Cost Of Revenue

Minority Interest vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Royalty Pharma Plc Minority Interest account and Cost Of Revenue. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Royalty Pharma's Minority Interest and Cost Of Revenue is -0.56. Overlapping area represents the amount of variation of Minority Interest that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Royalty Pharma Plc, assuming nothing else is changed. The correlation between historical values of Royalty Pharma's Minority Interest and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Minority Interest of Royalty Pharma Plc are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Minority Interest i.e., Royalty Pharma's Minority Interest and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

-0.56

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Minority Interest

Minority Interest is the portion of a subsidiary corporation stock that is not owned by the parent corporation. The magnitude of the minority interest in the subsidiary company is generally less than 50% of outstanding shares, otherwise the corporation would generally cease to be a subsidiary of the parent. Minority Interest can also be called non-controlling interest.All shareholders of Royalty Pharma Plc whose combined shares represent less than 50% of the total outstanding shares issued by Royalty Pharma have a minority interest in Royalty Pharma.

Cost Of Revenue

Cost of Revenue is found on Royalty Pharma Plc income statement and represents the costs associated with goods and services Royalty Pharma provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Royalty Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Royalty Pharma Plc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty Pharma Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

At this time, Royalty Pharma's Selling General Administrative is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 20.64 in 2025, whereas Sales General And Administrative To Revenue is likely to drop 0.06 in 2025.

	2022	2023	2024	2025 (projected)
Other Operating Expenses	1.3B	862.4M	972M	928.9M
Depreciation And Amortization	5.7M	395.1M	454.4M	477.1M

Other Operating Expenses Depreciation And Amortization

Royalty Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Common Stock Shares Outstanding	Short Term Investments	Inventory	Other Current Assets	Total Liab	Treasury Stock	Common Stock	Property Plant Equipment	Intangible Assets	Net Tangible Assets	Retained Earnings	Total Current Assets	Short Long Term Debt Total	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Non Current Liabilities Total
Total Assets		0.86	0.67	0.95	-0.4	0.76	0.6	0.81	0.44	0.21	0.29	0.25	0.94	-0.09	0.09	-0.46	-0.24	0.82	0.82	0.77	0.42	0.73	0.82	0.44	-0.04	0.6
Other Current Liab	0.86		0.67	0.85	-0.35	0.57	0.66	0.62	0.33	0.13	0.15	0.2	0.81	-0.1	0.1	-0.39	-0.2	0.64	0.59	0.76	0.28	0.47	0.6	0.4	0.16	0.51
Total Current Liabilities	0.67	0.67		0.74	-0.33	0.6	0.41	0.73	0.32	-0.21	-0.08	0.33	0.71	-0.16	0.04	-0.3	-0.2	0.57	0.55	0.5	0.17	0.67	0.6	0.58	-0.06	0.55
Total Stockholder Equity	0.95	0.85	0.74		-0.41	0.82	0.44	0.78	0.45	0.02	0.33	0.3	0.88	-0.11	0.06	-0.42	-0.23	0.76	0.78	0.67	0.3	0.76	0.79	0.59	-0.21	0.57
Other Liab	-0.4	-0.35	-0.33	-0.41		-0.29	-0.29	-0.34	-0.25	-0.27	-0.08	-0.21	-0.42	-0.71	-0.09	0.98	-0.08	-0.33	-0.33	-0.34	-0.14	-0.33	-0.3	-0.22	0.08	-0.27
Accounts Payable	0.76	0.57	0.6	0.82	-0.29		-0.01	0.83	0.31	-0.24	0.33	-0.06	0.62	-0.2	0.03	-0.27	-0.35	0.78	0.86	0.21	0.15	0.84	0.86	0.76	-0.51	0.47
Cash	0.6	0.66	0.41	0.44	-0.29	-0.01		0.31	0.4	0.39	-0.1	0.48	0.74	0.03	0.24	-0.39	0.03	0.37	0.25	0.92	0.32	0.15	0.2	-0.16	0.45	0.34
Other Assets	0.81	0.62	0.73	0.78	-0.34	0.83	0.31		0.23	-0.03	0.05	0.03	0.79	-0.28	0.2	-0.35	-0.39	0.91	0.91	0.43	0.52	0.92	0.87	0.61	-0.17	0.81
Common Stock Shares Outstanding	0.44	0.33	0.32	0.45	-0.25	0.31	0.4	0.23		-0.29	-0.24	0.52	0.49	0.24	-0.35	-0.26	0.18	0.13	0.19	0.44	0.01	0.28	0.35	0.5	-0.35	0.09
Short Term Investments	0.21	0.13	-0.21	0.02	-0.27	-0.24	0.39	-0.03	-0.29		0.34	-0.21	0.13	0.32	0.03	-0.34	0.01	0.18	0.11	0.35	0.53	-0.12	0.09	-0.63	0.71	0.12
Inventory	0.29	0.15	-0.08	0.33	-0.08	0.33	-0.1	0.05	-0.24	0.34		-0.24	0.16	-0.08	0.31	-0.13	-0.13	0.33	0.38	0.03	-0.16	0.17	0.19	-0.23	-0.17	-0.23
Other Current Assets	0.25	0.2	0.33	0.3	-0.21	-0.06	0.48	0.03	0.52	-0.21	-0.24		0.44	0.07	0.12	-0.22	0.2	-0.07	-0.1	0.59	-0.06	0.12	-0.14	0.17	-0.21	0.19
Total Liab	0.94	0.81	0.71	0.88	-0.42	0.62	0.74	0.79	0.49	0.13	0.16	0.44		-0.15	0.29	-0.49	-0.19	0.78	0.75	0.86	0.39	0.71	0.66	0.37	-0.05	0.63
Treasury Stock	-0.09	-0.1	-0.16	-0.11	-0.71	-0.2	0.03	-0.28	0.24	0.32	-0.08	0.07	-0.15		-0.42	-0.68	0.35	-0.31	-0.28	0.01	-0.05	-0.28	-0.11	-0.08	0.1	-0.24
Common Stock	0.09	0.1	0.04	0.06	-0.09	0.03	0.24	0.2	-0.35	0.03	0.31	0.12	0.29	-0.42		-0.16	-0.17	0.37	0.28	0.19	-0.09	0.21	-0.15	-0.26	-0.12	0.15
Property Plant Equipment	-0.46	-0.39	-0.3	-0.42	0.98	-0.27	-0.39	-0.35	-0.26	-0.34	-0.13	-0.22	-0.49	-0.68	-0.16		-0.08	-0.37	-0.36	-0.44	-0.16	-0.32	-0.3	-0.14	0.03	-0.26
Intangible Assets	-0.24	-0.2	-0.2	-0.23	-0.08	-0.35	0.03	-0.39	0.18	0.01	-0.13	0.2	-0.19	0.35	-0.17	-0.08		-0.41	-0.4	-0.02	-0.18	-0.35	-0.34	-0.16	0.04	-0.29
Net Tangible Assets	0.82	0.64	0.57	0.76	-0.33	0.78	0.37	0.91	0.13	0.18	0.33	-0.07	0.78	-0.31	0.37	-0.37	-0.41		0.98	0.46	0.45	0.88	0.86	0.37	-0.12	0.66
Retained Earnings	0.82	0.59	0.55	0.78	-0.33	0.86	0.25	0.91	0.19	0.11	0.38	-0.1	0.75	-0.28	0.28	-0.36	-0.4	0.98		0.38	0.42	0.91	0.9	0.46	-0.24	0.63
Total Current Assets	0.77	0.76	0.5	0.67	-0.34	0.21	0.92	0.43	0.44	0.35	0.03	0.59	0.86	0.01	0.19	-0.44	-0.02	0.46	0.38		0.37	0.3	0.34	0.04	0.28	0.46
Short Long Term Debt Total	0.42	0.28	0.17	0.3	-0.14	0.15	0.32	0.52	0.01	0.53	-0.16	-0.06	0.39	-0.05	-0.09	-0.16	-0.18	0.45	0.42	0.37		0.42	0.5	0.08	0.45	0.81
Net Debt	0.73	0.47	0.67	0.76	-0.33	0.84	0.15	0.92	0.28	-0.12	0.17	0.12	0.71	-0.28	0.21	-0.32	-0.35	0.88	0.91	0.3	0.42		0.85	0.64	-0.39	0.72
Non Current Assets Total	0.82	0.6	0.6	0.79	-0.3	0.86	0.2	0.87	0.35	0.09	0.19	-0.14	0.66	-0.11	-0.15	-0.3	-0.34	0.86	0.9	0.34	0.5	0.85		0.6	-0.15	0.62
Non Currrent Assets Other	0.44	0.4	0.58	0.59	-0.22	0.76	-0.16	0.61	0.5	-0.63	-0.23	0.17	0.37	-0.08	-0.26	-0.14	-0.16	0.37	0.46	0.04	0.08	0.64	0.6		-0.59	0.47
Cash And Short Term Investments	-0.04	0.16	-0.06	-0.21	0.08	-0.51	0.45	-0.17	-0.35	0.71	-0.17	-0.21	-0.05	0.1	-0.12	0.03	0.04	-0.12	-0.24	0.28	0.45	-0.39	-0.15	-0.59		0.11
Non Current Liabilities Total	0.6	0.51	0.55	0.57	-0.27	0.47	0.34	0.81	0.09	0.12	-0.23	0.19	0.63	-0.24	0.15	-0.26	-0.29	0.66	0.63	0.46	0.81	0.72	0.62	0.47	0.11

Click cells to compare fundamentals

Royalty Pharma Account Relationship Matchups

Royalty Pharma fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	21.1B	17.5B	16.8B	16.4B	18.2B	19.1B
Other Current Liab	297.1M	165.6M	161.4M	146.2M	242.5M	254.6M
Total Current Liabilities	307.9M	171.3M	1.2B	161.4M	1.3B	1.3B
Total Stockholder Equity	9.9B	5.8B	5.6B	6.5B	10.3B	10.9B
Accounts Payable	10.8M	5.6M	7.9M	15.2M	13.4M	14.0M
Cash	1.0B	1.5B	1.7B	477.0M	929.0M	566.1M
Other Assets	10.9B	5.1B	13.7B	13.5B	15.5B	16.3B
Common Stock Shares Outstanding	375.5M	414.8M	438.0M	602.9M	592.7M	441.1M
Short Term Investments	983M	1.3B	717.0M	18.3M	58.2M	55.3M
Other Current Assets	8.6M	6.6M	90.5M	3.8M	814.9M	855.7M
Total Liab	6.1B	7.3B	7.3B	6.3B	7.9B	8.3B
Common Stock	102K	106K	107K	45K	51.8K	49.2K
Intangible Assets	28.7M	5.7M	14.5M	1.8M	2.0M	1.9M
Net Tangible Assets	6.1B	4.8B	5.8B	5.6B	6.5B	3.7B
Retained Earnings	1.9B	2.3B	2.0B	2.5B	2.8B	1.6B
Total Current Assets	2.7B	2.9B	2.6B	1.3B	1.8B	2.4B
Short Long Term Debt Total	6.1B	14.0B	7.1B	6.1B	7.6B	8.0B
Net Debt	4.8B	5.6B	5.4B	5.7B	6.7B	5.8B
Non Current Assets Total	13.3B	14.6B	14.3B	15.1B	16.4B	13.0B
Non Currrent Assets Other	28.6M	4.1M	15.1M	14.1B	16.2B	17.0B
Cash And Short Term Investments	2.0B	2.8B	2.4B	495.3M	987.2M	1.3B
Liabilities And Stockholders Equity	21.1B	17.5B	16.8B	16.4B	18.2B	16.1B
Non Current Liabilities Total	5.8B	7.1B	6.1B	6.1B	6.6B	6.8B
Other Stockholder Equity	7.9B	3.5B	3.7B	4.0B	7.5B	4.4B
Long Term Debt	5.8B	7.1B	6.1B	6.1B	6.6B	6.9B
Net Receivables	39.2M	68.3M	727.9M	775.1M	27.0M	25.6M
Long Term Debt Total	6.0B	5.8B	7.1B	6.1B	7.0B	6.9B
Net Invested Capital	10.6B	12.9B	12.7B	12.7B	14.6B	13.6B
Long Term Investments	13.0B	14.4B	14.1B	15.1B	16.4B	14.6B
Accumulated Other Comprehensive Income	2.1M	34.4M	16.5M	63K	72.5K	68.8K
Capital Stock	102K	106K	107K	108K	97.2K	92.3K
Net Working Capital	2.4B	2.7B	1.4B	1.1B	548.5M	521.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Royalty Minority Interest vs Cost Of Revenue Analysis

Minority Interest vs Cost Of Revenue

Minority Interest vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Minority Interest

Cost Of Revenue

Royalty Pharma fundamental ratios Correlations

Royalty Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Royalty Pharma fundamental ratios Accounts

Also Currently Popular

Additional Tools for Royalty Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant Equipment	+ 0.98	Other Liab
Retained Earnings	+ 0.98	Net Tangible Assets
Total Stockholder Equity	+ 0.95	Total Assets
Total Liab	+ 0.94	Total Assets
Total Current Assets	+ 0.92	Cash
Net Debt	+ 0.92	Other Assets

Treasury Stock	- 0.71	Other Liab
Property Plant Equipment	- 0.68	Treasury Stock
Non Currrent Assets Other	- 0.63	Short Term Investments
Cash And Short Term Investments	- 0.59	Non Currrent Assets Other
Cash And Short Term Investments	- 0.51	Accounts Payable
Property Plant Equipment	- 0.49	Total Liab